GSK, Dynavax To Partner On TLR Compounds In Autoimmune, Inflammatory Disease
The latest option deal for GSK brings Dynavax $10 million upfront and potential milestones up to $200 million in each of four R&D programs.
The latest option deal for GSK brings Dynavax $10 million upfront and potential milestones up to $200 million in each of four R&D programs.